Baseline demographic and clinical characteristics in the QoL analysis set
| . | Category . | Overall, n (%) (N = 296) . | Axi-cel, n (%) (n = 165) . | SOC therapy, n (%) (n = 131) . |
|---|---|---|---|---|
| Geographic region | Australia | 4 (1.4) | 2 (1.2) | 2 (1.5) |
| Europe | 65 (22.0) | 31 (18.8) | 34 (26.0) | |
| Israel | 5 (1.7) | 4 (2.4) | 1 (0.8) | |
| North America | 222 (75.0) | 128 (77.6) | 94 (71.8) | |
| Observed baseline Eastern Cooperative | 0 | 170 (57.4) | 89 (53.9) | 81 (61.8) |
| Oncology Group performance status | 1 | 126 (42.6) | 76 (46.1) | 50 (38.2) |
| Age group | <65 y | 208 (70.3) | 119 (72.1) | 89 (67.9) |
| ≥65 y | 88 (29.7) | 46 (27.9) | 42 (32.1) | |
| Sex | Female | 100 (33.8) | 64 (38.8) | 36 (27.5) |
| Male | 196 (66.2) | 101 (61.2) | 95 (72.5) | |
| Race | Asian | 17 (5.7) | 11 (6.7) | 6 (4.6) |
| Black or African American | 14 (4.7) | 8 (4.8) | 6 (4.6) | |
| White | 247 (83.4) | 134 (81.2) | 113 (86.3) | |
| Other | 18 (6.1) | 12 (7.3) | 6 (4.6) | |
| Response to first-line therapy | Primary refractory | 208 (70.3) | 119 (72.1) | 89 (67.9) |
| Relapse ≤ 6 mo of first-line therapy | 16 (5.4) | 9 (5.5) | 7 (5.3) | |
| Relapse > 6 and ≤ 12 mo of first-line therapy | 72 (24.3) | 37 (22.4) | 35 (26.7) | |
| Second-line age-adjusted IPI total score | 0-1 | 171 (57.8) | 96 (58.2) | 75 (57.3) |
| 2–3 | 125 (42.2) | 69 (41.8) | 56 (42.7) | |
| Disease type per investigator | DLBCL, NOS | 187 (63.2) | 101 (61.2) | 86 (65.6) |
| HGBL with or without MYC and BCL2 and/or BCL6 rearrangement | 54 (18.2) | 37 (22.4) | 17 (13.0) | |
| Large-cell transformation from follicular lymphoma | 40 (13.5) | 19 (11.5) | 21 (16.0) | |
| Other | 15 (5.1) | 8 (4.8) | 7 (5.3) | |
| Cell of origin (molecular subgroup) | GCB | 143 (48.3) | 87 (52.7) | 56 (42.7) |
| Non-GCB | 84 (28.4) | 44 (26.7) | 40 (30.5) | |
| Not tested | 69 (23.3) | 34 (20.6) | 35 (26.7) | |
| Double-/triple-hit status per investigator | HGBL double hit | 40 (13.5) | 29 (17.6) | 11 (8.4) |
| HGBL triple hit | 17 (5.7) | 6 (3.6) | 11 (8.4) | |
| Negative | 178 (60.1) | 102 (61.8) | 76 (58.0) | |
| Not tested | 61 (20.6) | 28 (17.0) | 33 (25.2) |
| . | Category . | Overall, n (%) (N = 296) . | Axi-cel, n (%) (n = 165) . | SOC therapy, n (%) (n = 131) . |
|---|---|---|---|---|
| Geographic region | Australia | 4 (1.4) | 2 (1.2) | 2 (1.5) |
| Europe | 65 (22.0) | 31 (18.8) | 34 (26.0) | |
| Israel | 5 (1.7) | 4 (2.4) | 1 (0.8) | |
| North America | 222 (75.0) | 128 (77.6) | 94 (71.8) | |
| Observed baseline Eastern Cooperative | 0 | 170 (57.4) | 89 (53.9) | 81 (61.8) |
| Oncology Group performance status | 1 | 126 (42.6) | 76 (46.1) | 50 (38.2) |
| Age group | <65 y | 208 (70.3) | 119 (72.1) | 89 (67.9) |
| ≥65 y | 88 (29.7) | 46 (27.9) | 42 (32.1) | |
| Sex | Female | 100 (33.8) | 64 (38.8) | 36 (27.5) |
| Male | 196 (66.2) | 101 (61.2) | 95 (72.5) | |
| Race | Asian | 17 (5.7) | 11 (6.7) | 6 (4.6) |
| Black or African American | 14 (4.7) | 8 (4.8) | 6 (4.6) | |
| White | 247 (83.4) | 134 (81.2) | 113 (86.3) | |
| Other | 18 (6.1) | 12 (7.3) | 6 (4.6) | |
| Response to first-line therapy | Primary refractory | 208 (70.3) | 119 (72.1) | 89 (67.9) |
| Relapse ≤ 6 mo of first-line therapy | 16 (5.4) | 9 (5.5) | 7 (5.3) | |
| Relapse > 6 and ≤ 12 mo of first-line therapy | 72 (24.3) | 37 (22.4) | 35 (26.7) | |
| Second-line age-adjusted IPI total score | 0-1 | 171 (57.8) | 96 (58.2) | 75 (57.3) |
| 2–3 | 125 (42.2) | 69 (41.8) | 56 (42.7) | |
| Disease type per investigator | DLBCL, NOS | 187 (63.2) | 101 (61.2) | 86 (65.6) |
| HGBL with or without MYC and BCL2 and/or BCL6 rearrangement | 54 (18.2) | 37 (22.4) | 17 (13.0) | |
| Large-cell transformation from follicular lymphoma | 40 (13.5) | 19 (11.5) | 21 (16.0) | |
| Other | 15 (5.1) | 8 (4.8) | 7 (5.3) | |
| Cell of origin (molecular subgroup) | GCB | 143 (48.3) | 87 (52.7) | 56 (42.7) |
| Non-GCB | 84 (28.4) | 44 (26.7) | 40 (30.5) | |
| Not tested | 69 (23.3) | 34 (20.6) | 35 (26.7) | |
| Double-/triple-hit status per investigator | HGBL double hit | 40 (13.5) | 29 (17.6) | 11 (8.4) |
| HGBL triple hit | 17 (5.7) | 6 (3.6) | 11 (8.4) | |
| Negative | 178 (60.1) | 102 (61.8) | 76 (58.0) | |
| Not tested | 61 (20.6) | 28 (17.0) | 33 (25.2) |
Percentages are based on total evaluable in the QoL analysis set.
BCL2, B-cell lymphoma 2; BCL6, B-cell lymphoma 6; DLBCL, NOS, DLBCL not otherwise specified; GCB, germinal center B-cell like; HGBL, high-grade B-cell lymphoma; MYC, MYC gene; NOS, not otherwise specified.